Lord, Abbett & Co. LLC Agios Pharmaceuticals, Inc. Transaction History

Lord, Abbett & Co. LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$32.4 - $49.58 $5.73 Million - $8.76 Million	-176,761 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$46.17 - $68.1 $27,332 - $40,315	-592 Reduced 0.33%	176,761 $8.82 Million
Q1 2019 May 15, 2019	SELL	$45.92 - $67.67 $251,412 - $370,493	-5,475 Reduced 2.99%	177,353 $12 Million
Q4 2018 Feb 14, 2019	SELL	$42.73 - $76.53 $13.4 Million - $24 Million	-314,145 Reduced 63.21%	182,828 $8.43 Million
Q3 2018 Nov 14, 2018	SELL	$71.67 - $91.95 $51 Million - $65.4 Million	-711,110 Reduced 58.86%	496,973 $38.3 Million
Q2 2018 Aug 14, 2018	BUY	$73.22 - $99.55 $12 Million - $16.3 Million	163,737 Added 15.68%	1,208,083 $102 Million
Q1 2018 May 15, 2018	BUY	$59.83 - $86.53 $39.8 Million - $57.6 Million	665,684 Added 175.8%	1,044,346 $85.4 Million
Q4 2017 Feb 14, 2018	SELL	$52.12 - $72.33 $5.87 Million - $8.14 Million	-112,541 Reduced 22.91%	378,662 $21.6 Million
Q3 2017 Nov 14, 2017	BUY	$54.89 - $67.12 $12.3 Million - $15.1 Million	224,293 Added 84.03%	491,203 $32.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	266,910	266,910 $13.7 Million

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.89B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.